1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Cynata Therapeutics Limited
  6. News
  7. Summary
    CYP   AU000000CYP7

CYNATA THERAPEUTICS LIMITED

(CYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cynata Therapeutics Implements Strategic Manufacturing Deal with Fujifilm Subsidiary

12/29/2021 | 01:15am EDT


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CYNATA THERAPEUTICS LIMITED 12.50% 0.405 Delayed Quote.-33.95%
FUJIFILM HOLDINGS CORPORATION -0.32% 6801 Delayed Quote.-19.97%
All news about CYNATA THERAPEUTICS LIMITED
05/25Cynata Therapeutics Secures US FDA Clearance for Phase 2 Stem Cell Therapy Trial; Share..
MT
04/20Cynata Therapeutics Enrolls First Patients for Phase 1 Diabetic Foot Ulcer Trial; Share..
MT
04/20Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers
CI
03/07CYNATA THERAPEUTICS : Updated Investor Presentation
PU
02/27Cynata Therapeutics Limited Receives Notice of Decision to Grant A Patent from Chinese ..
CI
02/24Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 3..
CI
01/27Cynata Therapeutics to Secure Japanese Patent for Stem Cell Technology
MT
01/26Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan
CI
01/18Cynata Therapeutics Secures Tax Rebate for R&D Activities
MT
2021Cynata Therapeutics Implements Strategic Manufacturing Deal with Fujifilm Subsidiary
MT
More news
Financials
Sales 2021 1,55 M 1,09 M 1,09 M
Net income 2021 -7,69 M -5,44 M -5,44 M
Net cash 2021 26,7 M 18,9 M 18,9 M
P/E ratio 2021 -8,57x
Yield 2021 -
Capitalization 58,0 M 41,1 M 41,1 M
EV / Sales 2020 8,24x
EV / Sales 2021 29,5x
Nbr of Employees 2
Free-Float 85,7%
Chart CYNATA THERAPEUTICS LIMITED
Duration : Period :
Cynata Therapeutics Limited Technical Analysis Chart | CYP | AU000000CYP7 | MarketScreener
Technical analysis trends CYNATA THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,41 AUD
Average target price 2,00 AUD
Spread / Average Target 394%
Managers and Directors
Ross Alexander MacDonald Chief Executive Officer, MD & Executive Director
Geoff E. D. Brooke Non-Executive Chairman
Jolanta Airey Chief Medical Officer
Kilian Kelly Chief Operating Officer
Paul Kevin Wotton Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CYNATA THERAPEUTICS LIMITED-33.95%36
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-22.98%39 423
BIONTECH SE-40.00%37 588